International Psoriasis Council
Advancing Knowledge. Improving Care.
The IPC Psoriasis Masterclass is designed for dermatologists who are making treatment decisions and managing patients with psoriasis and are interested in specializing in psoriasis.
Over the five days of the course, IPC’s world-renowned experts will cover a variety of topics including the pathogenesis of psoriasis, new and emerging therapies and how to be an advocate for your patient.
The Masterclass agenda has been carefully developed to provide knowledge for daily use to the practicing dermatologist in an intimate environment designed to maximize faculty/participant interactions. Through lectures, panels, case-based discussions and question-answer sessions, attendees will obtain practical and important information for their dermatology practice.
The IPC Masterclass is open to dermatologists and general practitioners who meet the following criteria:
There is no cost to attend the program, but space is limited. The application deadline is May 22, 2023.
Timezones:
Tijuana: 11:00 – 1:00 pm (UTC -7)
Mexico City / Guatemala City / Juarez: 12:00 – 2:00 pm (UTC -6)
Bogota / Lima / Panama: 1:00 – 3:00 pm (UTC -5)
Santiago / Asunción / Santiago de los Caballeros: 2:00 – 4:00 pm (UTC -4)
Buenos Aires / São Paulo: 3:00 – 5:00 pm (UTC -3)
WELCOME + INTRODUCTION
Claudia de la Cruz
Clinical Manifestations of Psoriasis
Peter van de Kerkhof
Recategorization of Psoriasis Severity
Bruce Strober
Global Psoriasis Atlas
Darren Ashcroft
Patient Perspectives
Claudia de la Cruz
Clinical Cases
CLOSING COMMENTS
André Carvalho
WELCOME + INTRODUCTION
André Carvalho
Updates in Pathophysiology & Genetics
Matías Maskin
Psoriasis in Special Areas
Daniela Armijo
Updates on Comorbidities
Benjamin Hidalgo
Updates on Psoriatic Arthritis
Arthur Kavanaugh
Clinical Cases
CLOSING COMMENTS
Daniela Armijo
WELCOME + INTRODUCTION
Daniela Armijo
Generalized Pustular Psoriasis
Renata Magalhaes
Topical Therapies and Phototherapy
Fernando Valenzuela
Target to Treat & Methotrexate
André Carvalho
Biosimilars
Arnon Cohen
Clinical Cases
CLOSING COMMENTS
Claudia de la Cruz
WELCOME + INTRODUCTION
Claudia de la Cruz
Pediatric Psoriasis
Amy Paller
Anti TNF-a
César Gonzalez
Anti IL 17, Anti IL12/23 and Anti IL-23
Paolo Gisondi
New Oral Therapies
Andrew Pink
Clinical Cases
CLOSING COMMENTS
André Carvalho
WELCOME + INTRODUCTION
André Carvalho
Screening and Monitorization of Biologics
Tiago Torres
Personalized Treatment
Ron Vender
Biomarkers in Psoriasis
Jason Hawkes
My Challenging Cases
Wayne Gulliver
Clinical Cases
CLOSING COMMENTS
Claudia de la Cruz, André Carvalho, and Daniela Armijo
In this IPC commentary, Matias Maskin examines evidence from the BADBIR registry demonstrating that first-line biologic therapy in moderate to severe psoriasis leads to faster skin clearance, improved quality of life, and a lower risk of comorbidities. The analysis challenges traditional step-up approaches and supports earlier, patient-centered treatment strategies.
What were the key takeaways from the 2026 AAD Annual Meeting? IPC shares updates on diagnostic challenges, psoriasis therapies, and late-breaking research from leading experts.
A new regional collaboration led by IPC and partner organizations aims to improve diagnosis, treatment, and care coordination for psoriasis and psoriatic arthritis across Latin America.
IPC recognizes its 2025 Fellows as IPC Jr. Councilors following the completion of their fellowship. This transition recognizes their contributions to psoriasis research, education, and global collaboration, and marks their expanded role in the IPC network.
The International Psoriasis Council welcomes Mari Løset and Maxwell Sauder as new Councilors, supporting IPC’s global mission in psoriasis research and care.
In this Take Ten with IPC video, Dr. Leandro Leite discusses the most recent advances in psoriasis over the last year (March 2025 – March 2026). Topics include new guidelines, research, and recent studies.
